Pientzehuang Pharmaceutical reports Q3 dip, advances key TCM trial

Zhangzhou Pientzehuang Pharmaceutical Co., Ltd. reported a total operating income of 7.44 billion yuan for the first three quarters of 2025, marking an 11.93% decrease compared to the previous year. Net profit attributable to shareholders was 2.13 billion yuan, down 20.74% year-over-year. The medical manufacturing sector's revenue decreased by 12.93%, while the medical circulation sector saw an 8.45% decline. Overall gross profit margin decreased by 6.49 percentage points to 39.05%.

In a separate development, the company announced the successful first patient enrollment for its Wen Dan Tablet Phase III clinical trial. This innovative traditional Chinese medicine (TCM) targets mild to moderate generalized anxiety disorder. This marks a significant milestone, though the company states it will not have a material impact on 2025 financial results. Cumulative research and development investment for this drug project has reached approximately 55 million yuan.

The company cautioned investors about the inherent risks in drug development, including long cycles, multiple stages, high investment, and susceptibility to policy and market changes. It also noted that no other companies have received production approvals for TCM targeting generalized anxiety disorder of the phlegm-heat disturbing the mind pattern.